Although, ARID1A inactivation and alterations of the PI3K/AKT pathway frequently occur in CCA, the synthetic lethality by targeting the PI3K/AKT pathway in ARID1A-deficient CCA has not been studied. This evidence concerns the gene PIK3CA and cholangiocarcinoma.